The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study
Status
RECRUITING
Phase
NA
Age
≥ 18 Years
Enrollments
100
Conditions
Prostate CancerSummary
The overarching goal of this trial is to develop mechanisms to improve cardiovascular care among such prostate cancer patients receiving ADT by increasing patient awareness of individualized cardiovascular risk estimates and mitigation opportunities. Patients will be given access to a web-based quality improvement tool to educate patients of cardiovascular risks in prostate cancer and to inform them of their individualized, estimated cardiovascular risk and guideline-based risk mitigation recommendations. The study will assess the feasibility of this web-based application as a cardiovascular education tool for patients with prostate cancer. The study will also evaluate if completion of the web-based tool improves cardiovascular care access and risk mitigation for patients with prostate cancer.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Vivek Narayan, MD
- 215-360-0737
- [email protected]
Principal Investigator
- Vivek Narayan, MD
Eligibility Criteria
Inclusion Criteria:
* Men with prostate cancer > 18 years of age who are currently receiving or will be receiving treatment with ≥ 6 months of ADT
* Patients must be able to read and understand English.
Exclusion Criteria: n/a
Outcome Measures
Primary Outcome Measures
CARE-PC Web-Based Application Completion Rate
Secondary Outcome Measures
Patient acceptance and perception of the web-based application
Percent accuracy of patient-derived CV- and prostate cancer-related data elements
Prevalence of CV risk factors/disease at the time of CARE-PC web-based application participation
Proportion of participants with current cardiologist involvement in CV care at the time of web-based application participation
Proportion of participants engaging in CV care within 6 months of CARE-PC web application participation
Proportion of participants having changes in CV risk-reducing medications within 6 months of CARE-PC application participation.
Timeline
-
Last Updated
March 5, 2025 -
Start Date
October 3, 2023 -
Today
June 1, 2025 -
Completion Date ( Estimated )
June 30, 2026
Sponsors of this trial
-
Lead Sponsor
Vivek Narayan -
Collaborating Sponsors
National Comprehensive Cancer Network
RECRUITING 
≥ 18 Years